GSK

News

Stopwatch starts on reviews of GSK's long-acting asthma drug

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

News

GSK backs £50m Oxford University cancer vaccine programme

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

News

EU approves endometrial, lung cancer drugs from GSK and J&J

Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.

News

GSK confirms plan to buy cancer firm IDRx for $1bn

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

News

Is GSK prepping a $1bn takeover bid for IDRx?

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Stopwatch starts on reviews of GSK's long-acting asthma drug

GSK backs £50m Oxford University cancer vaccine programme

EU approves endometrial, lung cancer drugs from GSK and J&J

GSK confirms plan to buy cancer firm IDRx for $1bn

Is GSK prepping a $1bn takeover bid for IDRx?

11 blockbuster drugs to look out for in 2025

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

GSK

Editor's Picks